Udonitrectag

Phase 2Small molecule

RRECORDATI GROUP

Udonitrectag is one of 24 small molecule programs targeting Keratitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

KeratitisActive, not recruiting

KeratitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

55 competitors in Keratitis

#DrugCompanyPhaseTrials

Avelox

Neoral

Rayos

Decadron

AAspen Global Incorporated

Levaquin

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Acthar

1 8

OXERVATE

DDompé Farmaceutici S.p.A

Approved

1 9

Cenegermin

DDompé Farmaceutici S.p.A

Approved

1 10

Oxervate

DDompé Farmaceutici S.p.A

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Keratitis1 trial

REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients

Completed·RRECORDATI GROUP·Phase 2·NCT04276558·108 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Udonitrectag. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Udonitrectag compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Udonitrectag. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — RECORDATI GROUP company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RRECORDATI GROUP

Udonitrectag

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Keratitis1 trial

References

Drug Info

Quick Facts

Related News